Brief: MediciNova Announces MN-166 Identified As Promising Pharmacotherapy For Alcohol Use Disorder
22/02/2022 11:56
Feb 22 (Reuters) - MediciNova Inc MNOV.O :
* MEDICINOVA ANNOUNCES MN-166 (IBUDILAST) IDENTIFIED AS
PROMISING
PHARMACOTHERAPY FOR ALCOHOL USE DISORDER IN DRUGS
* MEDICINOVA INC - PRECLINICAL FINDINGS WHICH DEMONSTRATE
THAT
MN-166 (IBUDILAST) REDUCES ALCOHOL INTAKE ALIGN WITH PRIOR
STUDIES
* MEDICINOVA INC - MN-166 (IBUDILAST) APPEARS TO BE WELL
TOLERATED
Source text for Eikon: ID:nGNX8YKkTR
Further company coverage: MNOV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicinova
See all newsBrief: 3D Investment Partners Cuts Stake In Medicinova To 9.88% From 11.22%, Filing Shows
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake